IL17A and epilepsy: Therapeutically, in humans, some patients with autoimmune forms of epilepsy responded better to immunotherapy or anti-inflammatory treatment options [43, 44, 46–50], NSAIDs [45] or treatment inhibiting the differentiation and amplification of Th17 cells or neutralizing IL-17 [61] than to ASD.